Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese.

AIMS Compared with other categories of drugs, such as antibiotics and NSAIDs, antiepileptic therapies are associated with a high incidence of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). We previously reported that carbamazepine (CBZ)-SJS/TEN is strongly associated with the HLA-B*1502 in Han Chinese, which has been confirmed in other Southeast Asian countries where the allele is prevalent. Here, we extend the study of HLA susceptibility to three different antiepileptic drugs, phenytoin (PHT), lamotrigine (LTG) and oxcarbazepine (OXC), which have structure similarity to CBZ. MATERIALS & METHODS We carried out a case-control association study. We enrolled 26 PHT-, six LTG- and three OXC-induced SJS/TEN patients, 113 PHT-tolerant and 67 LTG-tolerant subjects who were on the drug, respectively, for more than 3 months without the adverse reactions, and 93 normal subjects from the general population. The HLA-A, B, C and DRB1 genotypes were determined. RESULTS We found that HLA-B*1502 was present in eight out of 26 (30.8%) PHT-SJS/TEN (OR: 5.1; 95% CI: 1.8-15.1; p = 0.0041), two out of six (33%) LTG-SJS (odds ratio [OR]: 5.1; 95% CI: 0.8-33.8; p = 0.1266) and three out of three (100%) OXC-SJS (OR: 80.7; 95% CI: 3.8-1714.4; p = 8.4 x 10(-4)) patients. In addition, HLA-B*1301, Cw*0801 and DRB1*1602 also showed an association with PHT-SJS/TEN (p = 0.0128-0.0281; OR: 3.0-4.3). CONCLUSION Our results indicate that OXC, PHT and LTG, which possess an aromatic ring just as CBZ does, when causing SJS/TEN, share a common risk allele. Aromatic antiepileptic drugs causing SJS/TEN in HLA-B*1502 carriers may act on a similar pathogenetic mechanism, although other genetic/nongenetic factor(s) may also contribute to the pathomechanism of the disease. We suggest that aromatic antiepileptic drugs, including CBZ, OXC and PHT, should be avoided in the B*1502 carrier and caution should also be exercised for LTG.

[1]  M. Nelson,et al.  High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients , 2009, Pharmacogenetics and genomics.

[2]  C. Hsiao,et al.  Oxcarbazepine‐induced Stevens–Johnson syndrome in a patient with HLA‐B*1502 genotype , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  Sheau-Fang Yang,et al.  Oxcarbazepine‐induced Stevens‐Johnson Syndrome: A Case Report , 2009, The Kaohsiung journal of medical sciences.

[4]  K. Suphapeetiporn,et al.  Carbamazepine and phenytoin induced Stevens‐Johnson syndrome is associated with HLA‐B*1502 allele in Thai population , 2008, Epilepsia.

[5]  Yuan-Tsong Chen,et al.  Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis , 2008, Nature Medicine.

[6]  C. Sotozono,et al.  HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2008, Pharmacogenomics.

[7]  C. Bazil,et al.  Cross-sensitivity of skin rashes with antiepileptic drug use , 2008, Neurology.

[8]  M. Muramatsu,et al.  Human leukocyte antigen genotypes in carbamazepine‐induced severe cutaneous adverse drug response in Japanese patients , 2008, The Journal of dermatology.

[9]  S. Lydersen,et al.  Cross-reactivity pattern of rash from current aromatic antiepileptic drugs , 2008, Epilepsy Research.

[10]  R. Toledano,et al.  Adverse Effects of Antiepileptic Drugs , 2008, Seminars in neurology.

[11]  L. Naldi,et al.  A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs , 2008, Pharmacogenetics and genomics.

[12]  T. Shiohara,et al.  HLA-B allele associations with certain drugs are not confirmed in Japanese patients with severe cutaneous drug reactions. , 2008, Acta dermato-venereologica.

[13]  S. Lhatoo,et al.  CNS Adverse Events Associated with Antiepileptic Drugs , 2008, CNS drugs.

[14]  L. Naldi,et al.  Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. , 2008, The Journal of investigative dermatology.

[15]  L. Hirsch,et al.  Comparison and predictors of rash associated with 15 antiepileptic drugs , 2007, Neurology.

[16]  P. Kwan,et al.  Association between HLA‐B*1502 Allele and Antiepileptic Drug‐Induced Cutaneous Reactions in Han Chinese , 2007, Epilepsia.

[17]  E. Bröcker,et al.  Anticonvulsant hypersensitivity syndrome: cross-reactivity with tricyclic antidepressant agents. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[18]  M. Pirmohamed,et al.  HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. , 2006, Pharmacogenomics.

[19]  M. Neuman,et al.  Antiepileptic drug-induced hypersensitivity syndrome reactions. , 2006, Current drug safety.

[20]  S. Jee,et al.  Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions , 2006, Pharmacogenetics and genomics.

[21]  W. Pan,et al.  Han Chinese Cell and Genome Bank in Taiwan: Purpose, Design and Ethical Considerations , 2006, Human Heredity.

[22]  M. Schumacher,et al.  A marker for Stevens-Johnson syndrome …: ethnicity matters , 2006, The Pharmacogenomics Journal.

[23]  B. Thiers.  HLA-B*5801 Allele as a Genetic Marker for Severe Cutaneous Adverse Reactions Caused by Allopurinol , 2006 .

[24]  Yuan-Tsong Chen,et al.  HLA-B genotyping to detect carbamazepine-induced Stevens-Johnson syndrome: implications for personalizing medicine. , 2005, Personalized medicine.

[25]  Yuan-Tsong Chen,et al.  Erratum: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol (Proceedings of the National Academy of Sciences of the United States of America (March 15, 2005) 102, 11 (4134-4139)) , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Yoshita,et al.  MRI of segmental zoster paresis , 2005, Neurology.

[27]  Martine Bagot,et al.  Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. , 2004, The Journal of allergy and clinical immunology.

[28]  Yuan-Tsong Chen,et al.  A marker for Stevens–Johnson syndrome , 2004 .

[29]  S. Helmers,et al.  The new antiepileptic drugs: scientific review. , 2004, JAMA.

[30]  D. Middleton.  Current and emerging technology for HLA typing , 2002, International journal of hematology.

[31]  K. Tokunaga,et al.  Diversity of HLA among Taiwan's indigenous tribes and the Ivatans in the Philippines. , 2001, Tissue antigens.

[32]  S. Knowles,et al.  Anticonvulsant Hypersensitivity Syndrome , 1999, Drug safety.

[33]  B. Wilder.  How About the New Antiepileptic Drugs? , 1994, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[34]  J. Roujeau.  The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. , 1994, The Journal of investigative dermatology.

[35]  B. Haldane.  THE ESTIMATION AND SIGNIFICANCE OF THE LOGARITHM OF A RATIO OF FREQUENCIES , 1956, Annals of human genetics.